Histogram
Visit number vs Plasminogen activator inhibitor-1 (PAI-1)
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Baseline Visit | 164 | 6.6 | ± 4.7 | 5.1 | 0.7 | 23.0 | 5 | 169 |
Month-6 Follow-up Visit | 110 | 6.9 | ± 5.2 | 5.5 | 0.9 | 27.6 | 59 | 169 |
Month-12 Follow-up Visit | 80 | 6.8 | ± 6.2 | 4.8 | 0.8 | 37.0 | 28 | 108 |
Treatment arm vs Plasminogen activator inhibitor-1 (PAI-1)
Baseline Visit
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 164 | 6.6 | ± 4.7 | 5.1 | 0.7 | 23.0 | 5 | 169 |
Conservative Medical Therapy (CMT) | 43 | 6.3 | ± 4.4 | 4.0 | 1.7 | 18.9 | 1 | 44 |
CMT + Sham CPAP | 41 | 6.2 | ± 4.9 | 5.5 | 0.7 | 19.9 | 1 | 42 |
CMT + Active CPAP | 41 | 6.6 | ± 4.4 | 5.1 | 0.9 | 17.1 | 1 | 42 |
CMT + Active CPAP + Motivational Enhancement | 39 | 7.6 | ± 5.1 | 6.2 | 1.9 | 23.0 | 2 | 41 |
Treatment arm vs Plasminogen activator inhibitor-1 (PAI-1)
Month-6 Follow-up Visit
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 110 | 6.9 | ± 5.2 | 5.5 | 0.9 | 27.6 | 59 | 169 |
Conservative Medical Therapy (CMT) | 29 | 7.2 | ± 4.5 | 6.1 | 1.6 | 14.8 | 15 | 44 |
CMT + Sham CPAP | 28 | 5.6 | ± 4.1 | 4.1 | 0.9 | 17.5 | 14 | 42 |
CMT + Active CPAP | 28 | 7.4 | ± 5.9 | 5.2 | 0.9 | 18.8 | 14 | 42 |
CMT + Active CPAP + Motivational Enhancement | 25 | 7.6 | ± 6.1 | 6.4 | 1.0 | 27.6 | 16 | 41 |
Treatment arm vs Plasminogen activator inhibitor-1 (PAI-1)
Month-12 Follow-up Visit
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 80 | 6.8 | ± 6.2 | 4.8 | 0.8 | 37.0 | 28 | 108 |
Conservative Medical Therapy (CMT) | 23 | 7.1 | ± 5.5 | 4.8 | 0.8 | 18.2 | 6 | 29 |
CMT + Sham CPAP | 21 | 5.1 | ± 4.2 | 4.1 | 1.4 | 17.0 | 6 | 27 |
CMT + Active CPAP | 18 | 8.6 | ± 9.4 | 5.4 | 1.9 | 37.0 | 8 | 26 |
CMT + Active CPAP + Motivational Enhancement | 18 | 6.7 | ± 4.8 | 6.6 | 0.9 | 16.0 | 8 | 26 |
Age at visit vs Plasminogen activator inhibitor-1 (PAI-1)
Baseline Visit
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 164 | 6.6 | ± 4.7 | 5.1 | 0.7 | 23.0 | 5 | 169 |
46.0 to 59.0 years | 42 | 6.9 | ± 5.4 | 5.4 | 0.7 | 23.0 | 1 | 43 |
59.0 to 66.0 years | 40 | 7.9 | ± 4.6 | 7.2 | 1.6 | 18.2 | 2 | 42 |
66.0 to 69.0 years | 42 | 6.9 | ± 4.7 | 5.3 | 1.0 | 18.9 | - | 42 |
70.0 to 76.0 years | 40 | 4.9 | ± 3.5 | 3.8 | 1.0 | 15.0 | 2 | 42 |
Age at visit vs Plasminogen activator inhibitor-1 (PAI-1)
Month-6 Follow-up Visit
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 110 | 6.9 | ± 5.2 | 5.5 | 0.9 | 27.6 | 59 | 169 |
46.0 to 60.0 years | 20 | 7.9 | ± 6.6 | 6.5 | 1.7 | 27.6 | 23 | 43 |
60.0 to 66.0 years | 30 | 7.4 | ± 5.6 | 5.5 | 1.0 | 18.6 | 12 | 42 |
66.0 to 70.0 years | 30 | 6.9 | ± 4.3 | 5.7 | 0.9 | 17.5 | 12 | 42 |
70.0 to 77.0 years | 30 | 5.7 | ± 4.4 | 4.9 | 0.9 | 16.9 | 12 | 42 |
Age at visit vs Plasminogen activator inhibitor-1 (PAI-1)
Month-12 Follow-up Visit
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 80 | 6.8 | ± 6.2 | 4.8 | 0.8 | 37.0 | 28 | 108 |
47.0 to 60.0 years | 16 | 6.8 | ± 4.9 | 4.9 | 1.9 | 16.7 | 11 | 27 |
60.0 to 66.0 years | 21 | 7.0 | ± 5.5 | 4.1 | 1.8 | 17.0 | 6 | 27 |
66.0 to 70.0 years | 21 | 8.7 | ± 8.7 | 6.7 | 1.1 | 37.0 | 6 | 27 |
71.0 to 77.0 years | 22 | 5.0 | ± 4.4 | 4.5 | 0.8 | 18.2 | 5 | 27 |
Gender vs Plasminogen activator inhibitor-1 (PAI-1)
Baseline Visit
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 164 | 6.6 | ± 4.7 | 5.1 | 0.7 | 23.0 | 5 | 169 |
Male | 107 | 6.2 | ± 4.6 | 4.6 | 0.9 | 23.0 | 3 | 110 |
Female | 57 | 7.5 | ± 4.7 | 6.7 | 0.7 | 18.9 | 2 | 59 |
Gender vs Plasminogen activator inhibitor-1 (PAI-1)
Month-6 Follow-up Visit
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 110 | 6.9 | ± 5.2 | 5.5 | 0.9 | 27.6 | 59 | 169 |
Male | 78 | 6.3 | ± 4.5 | 5.4 | 0.9 | 18.8 | 32 | 110 |
Female | 32 | 8.3 | ± 6.4 | 6.0 | 0.9 | 27.6 | 27 | 59 |
Gender vs Plasminogen activator inhibitor-1 (PAI-1)
Month-12 Follow-up Visit
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 80 | 6.8 | ± 6.2 | 4.8 | 0.8 | 37.0 | 28 | 108 |
Male | 53 | 6.9 | ± 6.3 | 5.1 | 0.8 | 37.0 | 19 | 72 |
Female | 27 | 6.8 | ± 6.1 | 4.6 | 1.6 | 27.2 | 9 | 36 |
Race vs Plasminogen activator inhibitor-1 (PAI-1)
Baseline Visit
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 163 | 6.6 | ± 4.7 | 5.1 | 0.7 | 23.0 | 5 | 168 |
White | 148 | 6.8 | ± 4.8 | 5.1 | 0.7 | 23.0 | 4 | 152 |
American Indian or Alaskan Native | - | - | - | - | - | - | - | - |
Black or African American | 10 | 5.4 | ± 2.8 | 5.5 | 0.9 | 9.7 | 1 | 11 |
Asian | 4 | 5.5 | ± 5.4 | 3.7 | 1.5 | 13.2 | - | 4 |
Native Hawaiian or other Pacific islander | - | - | - | - | - | - | - | - |
Other | 1 | 3.8 | - | 3.8 | 3.8 | 3.8 | - | 1 |
Multiple | - | - | - | - | - | - | - | - |
Race vs Plasminogen activator inhibitor-1 (PAI-1)
Month-6 Follow-up Visit
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 109 | 6.9 | ± 5.2 | 5.4 | 0.9 | 27.6 | 59 | 168 |
White | 102 | 7.0 | ± 5.3 | 5.4 | 0.9 | 27.6 | 50 | 152 |
American Indian or Alaskan Native | - | - | - | - | - | - | - | - |
Black or African American | 5 | 4.8 | ± 2.3 | 3.5 | 2.7 | 7.2 | 6 | 11 |
Asian | 2 | 9.4 | ± 5.3 | 9.4 | 5.7 | 13.2 | 2 | 4 |
Native Hawaiian or other Pacific islander | - | - | - | - | - | - | - | - |
Other | - | - | - | - | - | - | 1 | 1 |
Multiple | - | - | - | - | - | - | - | - |
Race vs Plasminogen activator inhibitor-1 (PAI-1)
Month-12 Follow-up Visit
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 80 | 6.8 | ± 6.2 | 4.8 | 0.8 | 37.0 | 28 | 108 |
White | 73 | 7.0 | ± 6.4 | 5.1 | 0.8 | 37.0 | 22 | 95 |
American Indian or Alaskan Native | - | - | - | - | - | - | - | - |
Black or African American | 5 | 5.5 | ± 2.8 | 4.6 | 3.5 | 10.5 | 4 | 9 |
Asian | 2 | 3.2 | ± 0.4 | 3.2 | 2.9 | 3.5 | 1 | 3 |
Native Hawaiian or other Pacific islander | - | - | - | - | - | - | - | - |
Other | - | - | - | - | - | - | 1 | 1 |
Multiple | - | - | - | - | - | - | - | - |